Kyverna Therapeutics (KYTX) Competitors $2.83 +0.06 (+2.17%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$2.84 +0.01 (+0.35%) As of 07:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYTX vs. TSHA, OPT, MRVI, BCYC, MGTX, BCAX, KURA, DNA, ATAI, and ZVRAShould you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Taysha Gene Therapies (TSHA), Opthea (OPT), Maravai LifeSciences (MRVI), Bicycle Therapeutics (BCYC), MeiraGTx (MGTX), Bicara Therapeutics (BCAX), Kura Oncology (KURA), Ginkgo Bioworks (DNA), atai Life Sciences (ATAI), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry. Kyverna Therapeutics vs. Its Competitors Taysha Gene Therapies Opthea Maravai LifeSciences Bicycle Therapeutics MeiraGTx Bicara Therapeutics Kura Oncology Ginkgo Bioworks atai Life Sciences Zevra Therapeutics Taysha Gene Therapies (NASDAQ:TSHA) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation. Is TSHA or KYTX more profitable? Kyverna Therapeutics has a net margin of 0.00% compared to Taysha Gene Therapies' net margin of -1,201.08%. Kyverna Therapeutics' return on equity of -51.66% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies-1,201.08% -104.93% -50.09% Kyverna Therapeutics N/A -51.66%-45.92% Which has stronger earnings & valuation, TSHA or KYTX? Taysha Gene Therapies has higher revenue and earnings than Kyverna Therapeutics. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTaysha Gene Therapies$8.33M62.62-$89.30M-$0.34-7.15Kyverna Therapeutics$7.03M17.40-$127.48M-$3.38-0.84 Do institutionals & insiders have more ownership in TSHA or KYTX? 77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 3.8% of Taysha Gene Therapies shares are held by company insiders. Comparatively, 22.0% of Kyverna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer TSHA or KYTX? Taysha Gene Therapies presently has a consensus price target of $8.20, indicating a potential upside of 237.45%. Kyverna Therapeutics has a consensus price target of $18.50, indicating a potential upside of 553.71%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Taysha Gene Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Kyverna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Does the media favor TSHA or KYTX? In the previous week, Taysha Gene Therapies had 2 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 5 mentions for Taysha Gene Therapies and 3 mentions for Kyverna Therapeutics. Taysha Gene Therapies' average media sentiment score of 0.71 beat Kyverna Therapeutics' score of 0.47 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kyverna Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, TSHA or KYTX? Taysha Gene Therapies has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Kyverna Therapeutics has a beta of 2.95, suggesting that its stock price is 195% more volatile than the S&P 500. SummaryKyverna Therapeutics beats Taysha Gene Therapies on 9 of the 16 factors compared between the two stocks. Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYTX vs. The Competition Export to ExcelMetricKyverna TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$119.72M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-0.8421.3126.2319.90Price / Sales17.40278.47413.23113.66Price / CashN/A41.4736.1356.90Price / Book0.467.518.045.38Net Income-$127.48M-$55.05M$3.15B$248.50M7 Day Performance-18.44%2.07%1.44%2.04%1 Month Performance1.43%4.84%3.62%4.84%1 Year Performance-63.15%5.37%34.68%20.23% Kyverna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYTXKyverna Therapeutics2.0782 of 5 stars$2.83+2.2%$18.50+553.7%-64.8%$119.72M$7.03M-0.8496News CoverageTSHATaysha Gene Therapies3.3969 of 5 stars$2.49+1.2%$7.57+204.1%+12.5%$528.07M$8.33M-7.32180Analyst ForecastOPTOpthea0.5008 of 5 stars$3.41+7.2%$1.33-60.9%+78.9%$524.84M$120K0.008News CoveragePositive NewsGap UpMRVIMaravai LifeSciences3.6338 of 5 stars$2.11+2.4%$6.64+214.6%-61.3%$524.60M$241.86M-1.85610BCYCBicycle Therapeutics4.1383 of 5 stars$7.23-2.6%$25.00+245.8%-62.4%$513.86M$35.28M-2.30240News CoverageMGTXMeiraGTx4.5358 of 5 stars$6.31-0.5%$24.00+280.3%+75.6%$509.52M$33.28M-2.72300News CoveragePositive NewsBCAXBicara Therapeutics1.7929 of 5 stars$9.18-1.5%$31.86+247.0%N/A$508.28MN/A0.0032KURAKura Oncology4.5599 of 5 stars$5.87+0.3%$24.50+317.4%-71.8%$506.46M$53.88M-2.80130DNAGinkgo Bioworks0.8305 of 5 stars$8.55-0.2%$5.77-32.6%N/A$501.62M$227.04M-0.93640ATAIatai Life Sciences3.1017 of 5 stars$2.02-18.5%$8.67+329.0%+111.5%$496.84M$310K-2.2280Trending NewsAnalyst ForecastOptions VolumeGap UpHigh Trading VolumeZVRAZevra Therapeutics2.422 of 5 stars$9.00-0.4%$22.29+147.6%+115.8%$494.31M$40.59M-4.7420Analyst ForecastGap Up Related Companies and Tools Related Companies TSHA Alternatives OPT Alternatives MRVI Alternatives BCYC Alternatives MGTX Alternatives BCAX Alternatives KURA Alternatives DNA Alternatives ATAI Alternatives ZVRA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYTX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KYTX Stock Alerts